Press Releases

Date Title and Summary Additional Formats
Toggle Summary AMICUS THERAPEUTICS APPOINTS JOHN F. CROWLEY CHAIRMAN AND CEO
New Executives Named to Management Team
View HTML
Toggle Summary AMICUS THERAPEUTICS INITIATES PHASE I TRIAL WITH LEAD COMPOUND AT1001 FOR THE TREATMENT OF FABRY DISEASE
AMICUS THERAPEUTICS INITIATES PHASE I TRIAL WITH LEAD COMPOUND AT1001 FOR THE TREATMENT OF FABRY DISEASE New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with
View HTML
Toggle Summary AMICUS THERAPEUTICS RAISES $31 MILLION IN SERIES B FINANCING
AMICUS THERAPEUTICS RAISES $31 MILLION IN SERIES B FINANCING New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an initial focus on lysosomal storage
View HTML
Toggle Summary AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE
AMICUS THERAPEUTICS RECEIVES U.S. ORPHAN DRUG DESIGNATION FOR AT1001 IN THE TREATMENT OF FABRY DISEASE New Brunswick, NJ - Amicus Therapeutics, Inc., an emerging drug development company focused on the development of a novel therapeutic approach to the treatment of human genetic disorders, with an
View HTML
Toggle Summary AMICUS THERAPEUTICS EXPANDS INTELLECTUAL PROPERTY ESTATE
Issuance of Fourth U.S. Patent Secures Company's Proprietary Position
View HTML